The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.

The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.

US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents: London, UK Thursday, October 17, 2 ...

GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...

Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action ...

The oncology landscape is evolving, with a marked rise in cancer incidence among young adults globally. This challenges the traditional view of cancer as primarily an ailment of the elderly. The ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.

(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...

London open The FTSE 100 is expected to open 17 points higher on Wednesday, having closed down 0.52% on Tuesday at 8,249.28.

Here is what you need to know at the London market open: FTSE 100: opened up 56.75 points, or 0.7%, at 8,306.03 Hang Seng: up 0.3% at 20,371.80 Nikkei 225: closed down 1.8% at 39,180.30 S&P/ASX 200: ...

GSK plc (GSK, GSK.L) announced the FDA has accepted the New Drug Application for gepotidacin, an oral antibiotic with a mechanism of ...